At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
LY3502970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Group, Open-Label, Single-Period, Phase 1 Study to Determine the Absolute Bioavailability of LY3502970 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3502970 and [14C]-LY3502970 for Healthy. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedOct 2023
Enrollment StartOct 2023
Primary CompletionJan 2024
TodayJul 2026
First PostedOct 17, 2023
Enrollment StartOct 19, 2023
Primary CompletionJan 5, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.7 years ago
Interventions
LY3502970drug
Administered orally
[14C]-LY3502970drug
Administered IV